FDA Official Gives Policy Update On Lab-Developed Tests
This article was originally published in The Gray Sheet
Executive Summary
Most laboratory-developed tests have no predicates, said Elizabeth Mansfield, director of personalized medicine in CDRH’s diagnostics office, hinting that many may require pre-market submissions that go beyond 510(k) review standards once the agency initiates plans for active oversight of the category.
You may also be interested in...
FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
Senate Bill In The Works For Laboratory-Developed Tests
Sen. Orrin Hatch, R-Utah, is developing a bill that would create a new pre-market review process for laboratory-developed tests, even as FDA plans to pursue such oversight without legislation.